Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company advancing targeted therapies for endocrine-driven breast cancers. This page provides investors and healthcare professionals with timely updates on clinical developments, financial disclosures, and strategic initiatives.
Access consolidated information about OLMA's lead candidate palazestrant (OP-1250), an oral complete estrogen receptor antagonist/SERD, and other pipeline assets like the KAT6 inhibitor OP-3136. Track regulatory milestones, partnership announcements, and peer-reviewed research findings in one centralized location.
Key updates include clinical trial progress, scientific conference presentations, and financial results. All content is sourced from official company communications and verified industry reports to ensure accuracy.
Bookmark this page for streamlined access to OLMA's latest developments in women's oncology therapeutics. Check regularly for essential updates impacting treatment innovation and corporate strategy.
Olema Pharmaceuticals reported promising preliminary results for its OP-1250 Phase 1/2 study, showing favorable tolerability and significant anti-tumor activity. Results from 68 patients indicated a well-tolerated drug with an exposure rate 20 times that of fulvestrant, and 41% of patients experienced tumor reductions. The company maintains a strong financial position with $222.6 million in cash as of September 30, 2022, expected to fund operations through late 2024. However, the net loss increased to $22.7 million, primarily due to R&D investments in OP-1250.
Olema Pharmaceuticals (Nasdaq: OLMA) announced the granting of stock options to two new employees totaling 40,400 shares, effective November 1, 2022. This decision was approved by the Compensation Committee under the 2022 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with an exercise price of $3.72 per share. Olema focuses on developing targeted therapies for women’s cancers, notably its lead candidate OP-1250, which has received FDA Fast Track designation and is currently in Phase 2 trials.
Olema Pharmaceuticals (Nasdaq: OLMA) announces its participation in several investor conferences this November. Key events include a presentation at the Credit Suisse 31st Annual Healthcare Conference on November 9 at 9:10 AM PT, a fireside chat at the Jefferies London Healthcare Conference on November 16 at 11:30 AM GMT, and a virtual fireside chat at the Evercore ISI HealthCONx Conference on November 29 at 2:40 PM ET. Live webcasts and materials will be accessible on Olema's website for at least 30 days.
Olema focuses on developing targeted therapies for women’s cancers, highlighted by its lead product candidate, OP-1250.
Olema Pharmaceuticals (Nasdaq: OLMA) announced preliminary Phase 1/2 clinical results for OP-1250, a treatment for metastatic breast cancer, showcased at the 34th EORTC-NCI-AACR Symposium. The study involved 68 patients, revealing OP-1250's favorable tolerability, with drug exposure 20 times higher than fulvestrant at the effective dose. Strong anti-tumor activity was noted, with 41% of patients showing tumor reduction. The company plans to initiate a pivotal Phase 3 study mid-2023, aiming to advance OP-1250 as a leading endocrine therapy for ER+ breast cancer.
Olema Pharmaceuticals (Nasdaq: OLMA) announced the presentation of updated clinical results from the OP-1250-001 study at the 34th EORTC-NCI-AACR Symposium in Barcelona, occurring October 26-28, 2022. The study focuses on OP-1250, an oral compound for advanced ER-positive, HER2-negative breast cancer, with preliminary Phase 1/2 results to be showcased. A dedicated investor webcast is scheduled for October 26, 2022, at 8:00 a.m. ET, led by Dr. Erika Hamilton and Olema's management.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the grant of stock options totaling 58,300 shares to four new employees, effective October 3, 2022. These options were approved by the Board’s Compensation Committee under the 2022 Inducement Plan, with a 10-year term and an exercise price of $2.91 per share. The options vest over four years, with 25% vesting on the first anniversary and the rest in monthly installments. This move aligns with Nasdaq Listing Rule 5635(c)(4) and underscores Olema's commitment to attracting talent in the competitive biotech landscape.
Olema Pharmaceuticals (Nasdaq: OLMA) announced that Shane Kovacs, COO and CFO, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 2:30 p.m. ET. A live webcast of the chat will be available on Olema's website and archived for 14 days. Olema, focused on therapies for women's cancers, is advancing its lead product candidate, OP-1250, an estrogen receptor antagonist and degrader, in clinical trials for ER-positive breast cancer.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, has announced the granting of stock options to three new employees. Effective September 1, 2022, a total of 72,200 shares will be available for purchase at an exercise price of $3.69 per share, equivalent to the last reported sale price on that date. The stock options will vest over four years, with 25% vesting after one year and the remainder in monthly installments, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals has received Fast Track designation from the FDA for OP-1250, targeting ER+/HER2- metastatic breast cancer.
The company reported a strong cash position of $240.7 million as of June 30, 2022, sufficient to support operations until the second half of 2024.
Despite a net loss of $32.9 million in Q2 2022, up from $16.4 million the previous year, Olema continues to advance its clinical development program, having selected a recommended Phase 2 dose of 120 mg for OP-1250.
Olema Pharmaceuticals has moved OP-1250, a complete estrogen receptor antagonist and selective ER degrader, into Phase 2 clinical development for ER+/HER2- metastatic breast cancer. Phase 1b expansion results noted encouraging anti-tumor activity with 4 partial responses observed among 31 evaluable patients. 50 patients received treatment at two dose levels. The recommended Phase 2 dose is set at 120 mg once daily. Enrollment in Phase 2 includes distinct cohorts, and a pivotal trial is planned for mid-2023.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
